Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Jcr Pharmaceuticals Co. Ltd.
Headquarters: Ashiya, Hyogo, Japan
Website: http://www.jcrpharm.co.jp
Year Founded: 1975
Status: Public
Industry Sector: HealthTechnology
CEO: Shin Ashida
Number Of Employees: 934
Enterprise Value: $744,557,607
PE Ratio: -282.28
Exchange/Ticker 1: Tokyo:4552
Exchange/Ticker 2: N/A
Latest Market Cap: $417,034,947
BioCentury | Feb 28, 2025
Product Development
Rare Disease Spotlight: A genetic seizure disorder with a growing market, pipeline
As the first Dravet syndrome products establish the market, the pipeline moves toward selective small molecules and genetic therapies
BioCentury | Dec 20, 2024
Product Development
Long-awaited FDA approval for Mesoblast marks a first in the U.S.
Nearly a decade after Japanese approval, mesenchymal stromal cell therapy approved for pediatric GvHD
BioCentury | Apr 18, 2024
Product Development
Rare disease spotlight: a leukodystrophy with small pipeline behind first approval
At least three MLD programs are coming up behind Orchard’s Lenmeldy, although three others were recently discontinued
BioCentury | Mar 1, 2024
Product Development
Rare disease spotlight: enzyme replacement therapy for the brain
At least seven companies aim to overcome the challenge of delivering an enzyme across the blood-brain barrier to treat MPS IIIA
BioCentury | Oct 1, 2021
Finance
Sept. 30 Quick Takes: Advent closes €86M second fund
Data for Sanofi’s anti-OX40 mAb, plus TrialSpark’s $156M series C, Minerva’s next step toward schizophrenia submission and more
BioCentury | Jul 30, 2021
Distillery Therapeutics
In utero base editing may treat Mucopolysaccharidosis type I
DISEASE CATEGORY: Endocrine/Metabolic
INDICATION: Mucopolysaccharidosis In utero base editing could help treat mucopolysaccharidosis type I, a lethal lysosomal storage disease caused by a G to A
INDICATION: Mucopolysaccharidosis In utero base editing could help treat mucopolysaccharidosis type I, a lethal lysosomal storage disease caused by a G to A
BioCentury | May 20, 2021
Deals
Neuro deal flow: pharmas pinning hopes on new modalities, delivery technologies
The last three years of deals prioritize new modalities against known targets and CNS entry over discovery of new targets
BioCentury | May 13, 2019
Company News
May 13 Company Quick Takes: PeptiDream/JCR, Grail, Lilly, Onconova/HanX, Regeneron
BioCentury | Sep 1, 2018
Politics, Policy & Law
Stepping Through
How regulatory innovation lays the foundation for new business models
BioCentury | Jul 27, 2017
Strategy
FDA’s regeneration
What the regenerative medicine industry wants from FDA this September
Items per page:
1 - 10 of 73